Biologics Market: Global Industry Analysis and Forecast (2023-2029) by Product, Application and Region

Biologics Market size was valued at US$ 360.17 Bn. in 2022 and the total revenue is expected to grow at 9.1 % through 2023 to 2029, reaching nearly US$ 662.66 Bn.

Biologics Market Overview:

Biologics are drugs made from complex molecules manufactured using living plants, microorganisms, or animal cells. The Biologics drugs market has been exhibiting an aggressive competition divided among a handful of household organizations and count of the world’s best pharmaceutical companies. There are some examples of biologics such as Lantus (insulin glargine), Humira (adalimumab), Herceptin (trastuzumab), Avastin (bevacizumab), and Botox (onabotulinumtoxina). Biologics have witnessed millions of dollars put in by pharmaceutical behemoths like Sandoz, AstraZeneca, Novartis, and Eli Lilly and Co., and others.Biologics MarketTo know about the Research Methodology :- Request Free Sample Report

Global Biologics Market Dynamics:

In the past five years, over US$ 1.5 billion have been invested by top 10 pharmaceutical giants which have interpreted into capacity expansion and focused research and development. Pharmaceutical companies are earning strong revenues through best prices value increased in their profit margins xx%. Factors like product approvals and the ability of biologics to effectively treat significantly complex diseases, which was close to incredible earlier, have been key for biologics market growth. Pharmaceutical companies patenting biologics products have been projected to make healthy gains during the forecast period. With the vigorous growth in the biopharmaceutical industry, over 14% of biomolecules that enter phase I of clinical trials have been expected to be likely approved as a drug. Growing annual product approvals and strong biologics channel has been an indication of robust development of the world biologics market. For example, the anti-inflammatory drug Humira is not only the best-selling drug, but it is also one of the best-selling drugs globally. But, high capital investment essential for research and development could hinder the demand in the international biologics market. Only biopharmaceutical companies have been observed to enter the market because of a costly initial setup. A successful product launch primarily requires an over US$1.0 billion investment and takes nearly 9 years. Furthermore, the regulatory approval of biologics is quite detailed since the molecules are complex. Manufacturers in Biologics are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

Global Biologics Market Segment Analysis:

The global Biologics Market is segmented by Product and Application. Based on Product, the global Biologics market is segmented into Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cell Therapy, and Gene Therapy. The Monoclonal Antibodies segment held the largest market share of 42.9% in 2022. Extensive growth is credited to the increasing demand for personalized therapies in various regions. Additionally, extensive researches in antibodies to discover targeted therapies for a variety of diseases, like different types of infections, cancers, and various immunological disorders, are projected to propel the market. Based on Application, the global Biologics market is segmented into Oncology, Infectious Diseases, Immunology, and Autoimmune Diseases. The Immunology segment held the largest market share of xx% in 2022 and it is expected to grow at the highest CAGR of xx% in the global Biologics market during the forecast period. Biologics are utilised to treat autoimmune illnesses such as inflammatory arthritis, rheumatoid arthritis, and psoriatic arthritis, which is driving the market growth. Biologics Market1

Global Biologics Market Regional Insights:

North America held the largest market share of 51% in 2022 and is expected to remain its leading position in the global Biologics market during the forecast period. Because of, growth in this regional market is attributed to intensive research and development activities, novel drug formulations, and a large number of clinical trials focused on large-molecule drug discovery. Asia Pacific held the 2nd largest market share of 21% in 2022. Because of the rising prevalence of chronic conditions such as diabetes, as well as the increased number of healthcare tourists in the regions of the world. The objective of the report is to present a comprehensive analysis of the global Biologics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also helps in understanding the global Biologics Market dynamic, structure by analyzing the market segments and project the global Biologics Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Biologics Market make the report investor’s guide.

Global Biologics Market Scope: Inquire before buying

Biologics Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2018 to 2022 Market Size in 2022: US $ 360.17 Bn.
Forecast Period 2023 to 2029 CAGR: 9.1% Market Size in 2029: US $ 662.66 Bn.
Segments Covered: by Disease Category • Oncology • Infectious Diseases • Immunological Disorders • Cardiovascular Disorders • Hematological Disorders • Others
by Manufacturing • In-house • Outsource
by Product • Monoclonal Antibodies

 By application o Diagnostic o Therapeutic o Protein Purification o Others

 By type o Murine o Chimeric o Humanized o Human o Others

• Vaccines • Recombinant Proteins • Antisense, RNAi, & Molecular Therapy • Others
by Source • Microbial • Mammalian • Others

Global Biologics Market, by Region

North America (United States, Canada and Mexico) • Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) • Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) • Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) • South America (Brazil, Argentina Rest of South America)

Global Biologics Market Key Players

• Sandoz • Pfizer • Teva Pharmaceutical • Celltrion • Biocon • Amgen • Samsung Biologics • Mylan • Dr. Reddy's Laboratories • Stada Arzneimittel AG • Pernix Therapeutics • Purdue Pharma L.P. • Sanofi Pasteur • SkyePharma • Takeda Pharmaceutical Company • AbbVie Inc. • Eli Lilly and Company • F. Hoffmann-La Roche AG • GlaxoSmithkline PLC • G. Chem Ltd. • AstraZeneca Plc

Frequently Asked Questions:

1] What segments are covered in Biologics Market report? Ans. The segments covered in Biologics Market report are based on Product and Application. 2] Which region is expected to hold the highest share in the global Biologics Market? Ans. North America is expected to hold the highest share in the global Biologics Market. 3] What is the market size of global Biologics Market by 2029? Ans. The market size of global Biologics Market by 2029 is US $ 662.66 Bn. 4] Who are the top key players in the global Biologics Market? Ans. Sandoz, Pfizer, Teva Pharmaceutical, Celltrion and Biocon are the top key players in the global Biologics Market. 5] What was the market size of global Biologics Market in 2022? Ans. The market size of global Biologics Market in 2022 was US $ 360.17 Bn. 6] By Application, What segments are covered in global Biologics Market report? Ans. The segments covered in global Biologics Market report by application are Oncology, Infectious Diseases, Immunology and Autoimmune Diseases.
1. Global Biologics Market: Research Methodology 2. Global Biologics Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Biologics Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Biologics Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Biologics Market Segmentation 4.1 Global Biologics Market, by Disease Category (2022-2029) • Oncology • Infectious Diseases • Immunological Disorders • Cardiovascular Disorders • Hematological Disorders • Others 4.2 Global Biologics Market, by Manufacturing(2022-2029) • In-house • Outsource 4.3 Global Biologics Market, by Product (2022-2029) • Monoclonal Antibodies  By application o Diagnostic o Therapeutic o Protein Purification o Others  By type o Murine o Chimeric o Humanized o Human o Others • Vaccines • Recombinant Proteins • Antisense, RNAi, & Molecular Therapy • Others 4.4 Global Biologics Market, by Source (2022-2029) • Microbial • Mammalian • Others 5. North America Biologics Market(2022-2029) 5.1 North America Biologics Market, by Disease Category (2022-2029) • Oncology • Infectious Diseases • Immunological Disorders • Cardiovascular Disorders • Hematological Disorders • Others 5.2 North America Biologics Market, by Manufacturing(2022-2029) • In-house • Outsource 5.3 North America Biologics Market, by Product (2022-2029) • Monoclonal Antibodies  By application o Diagnostic o Therapeutic o Protein Purification o Others  By type o Murine o Chimeric o Humanized o Human o Others • Vaccines • Recombinant Proteins • Antisense, RNAi, & Molecular Therapy • Others 5.4 North America Biologics Market, by Source (2022-2029) • Microbial • Mammalian • Others 5.5 North America Biologics Market, by Country (2022-2029) • United States • Canada • Mexico 6. Europe Biologics Market (2022-2029) 6.1. European Biologics Market, by Disease Category (2022-2029) 6.2. European Biologics Market, by Manufacturing(2022-2029) 6.3. European Biologics Market, by Product (2022-2029) 6.4. European Biologics Market, by Source (2022-2029) 6.5. European Biologics Market, by Country (2022-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Biologics Market (2022-2029) 7.1. Asia Pacific Biologics Market, by Disease Category (2022-2029) 7.2. Asia Pacific Biologics Market, by Manufacturing(2022-2029) 7.3. Asia Pacific Biologics Market, by Product (2022-2029) 7.4. Asia Pacific Biologics Market, by Source (2022-2029) 7.5. Asia Pacific Biologics Market, by Country (2022-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Biologics Market (2022-2029) 8.1 Middle East and Africa Biologics Market, by Disease Category (2022-2029) 8.2. Middle East and Africa Biologics Market, by Manufacturing(2022-2029) 8.3. Middle East and Africa Biologics Market, by Product (2022-2029) 8.4. Middle East and Africa Biologics Market, by Source (2022-2029) 8.5. Middle East and Africa Biologics Market, by Country (2022-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Biologics Market (2022-2029) 9.1. South America Biologics Market, by Disease Category (2022-2029) 9.2. South America Biologics Market, by Manufacturing(2022-2029) 9.3. South America Biologics Market, by Product (2022-2029) 9.4. South America Biologics Market, by Source (2022-2029) 9.5. South America Biologics Market, by Country (2022-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Sandoz. 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Pfizer 10.3. Teva Pharmaceutical 10.4. Celltrion 10.5. Biocon 10.6. Amgen 10.7. Samsung Biologics 10.8. Mylan 10.9. Dr. Reddy's Laboratories 10.10. Stada Arzneimittel AG 10.11. Pernix Therapeutics 10.12. Purdue Pharma L.P. 10.13. Sanofi Pasteur 10.14. SkyePharma 10.15. Takeda Pharmaceutical Company 10.16. AbbVie Inc. 10.17. Eli Lilly and Company 10.18. F. Hoffmann-La Roche AG 10.19. GlaxoSmithkline PLC 10.20. G. Chem Ltd. 10.21. AstraZeneca Plc

About This Report

Report ID 37255
Category Healthcare
Published Date April 2023
Updated Date
  • INQUIRE BEFORE BUYING